FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer By Ogkologos - August 26, 2026 44 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-B15/EV-304 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Cancer Research UK thanks Tania Bryer for a decade of fundraising... April 19, 2022 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast... July 1, 2021 ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding... September 25, 2025 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... Couple Married For 48 Years Shared A Touching Moment As They...
